Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys
| Autor: | A. Block, R.C. Manfro, M. B. Harler, Valter Duro Garcia, Josep M. Grinyó, M Rial, Stefan Vitko, Nassim Kamar, Antoine Durrbach, Sander Florman, Peter Lang, Thomas Becker, Pablo U. Massari, Josep M. Campistol, Yves Vanrenterghem, J. O. Medina Pestana, T. Duan, Mark A. Schnitzler |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Immunoconjugates medicine.medical_treatment Urology Renal function Kidney Function Tests Belatacept Abatacept Postoperative Complications Risk Factors medicine Immunology and Allergy Humans Pharmacology (medical) Transplantation Kidney business.industry Graft Survival Immunosuppression Middle Aged medicine.disease Prognosis Kidney Transplantation Lymphoproliferative Disorders Surgery Survival Rate Regimen medicine.anatomical_structure Cyclosporine Population study Kidney Failure Chronic Female business Immunosuppressive Agents Kidney disease medicine.drug Follow-Up Studies Glomerular Filtration Rate |
| Zdroj: | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 12(3) |
| ISSN: | 1600-6143 |
| Popis: | Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria donor kidney recipients. We report 3-year outcomes from a randomized, phase III study in recipients of de novo ECD kidneys (n = 543) assigned (1:1:1) to either a more intensive (MI) or less intensive (LI) belatacept regimen, or cyclosporine. Three hundred twenty-three patients completed treatment by year 3. Patient survival with a functioning graft was comparable between groups (80% in MI, 82% in LI, 80% in cyclosporine). Mean calculated GFR (cGFR) was 11 mL/min higher in belatacept-treated versus cyclosporine-treated patients (42.7 in MI, 42.2 in LI, 31.5 mL/min in cyclosporine). More cyclosporine-treated patients (44%) progressed to GFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text